English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine Clinical Trials
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore
Apr 14, 2023 17:18 HKT
亿胜生物与郡是深圳签订皮耐克®可吸收性敷料在中国大陆的独家代理协议
Apr 11, 2023 13:00 HKT
億勝生物與郡是深圳簽訂皮耐克®可吸收性敷料在中國大陸的獨家代理協議
Apr 11, 2023 12:59 HKT
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC Absorbable Dressing in Mainland China
Apr 11, 2023 12:58 HKT
TrialWire Patient Recruitment Platform Launches AI Pre-recruit to Cut Recruitment Time by 50%
Apr 11, 2023 08:00 HKT
冠科美博(Apollomics Inc.)宣布完成和SPAC Maxpro合并,并在纳斯达克上市
Mar 30, 2023 20:31 HKT
冠科美博(Apollomics Inc.)宣佈完成和SPAC Maxpro合併,並在納斯達克上市
Mar 30, 2023 20:30 HKT
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
Mar 30, 2023 20:29 HKT
Singapore family cord blood bank Cryoviva upgrades to AXP II System for cord blood processing
Mar 21, 2023 08:30 HKT
亿胜生物公布2022年度业绩
Mar 08, 2023 20:30 HKT
億勝生物公布2022年度業績
Mar 08, 2023 20:29 HKT
Essex Bio-Technology Announces 2022 Annual Financial Results
Mar 08, 2023 20:28 HKT
“天然分子” 的葫蘆裡,給慢病埋的什麼藥?
Mar 03, 2023 09:48 HKT
“天然分子” 的葫芦里,给慢病埋的什么药?
Mar 03, 2023 09:47 HKT
亿胜生物与复宏汉霖签订治疗年龄相关性黄斑变性全球共同开发及独家许可协议之经修订协议
Feb 22, 2023 18:50 HKT
億勝生物與復宏漢霖簽訂治療年齡相關性黃斑變性全球共同開發及獨家許可協議之經修訂協議
Feb 22, 2023 18:49 HKT
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration
Feb 22, 2023 18:48 HKT
疫苗开发不断变化的全球格局:Novotech 和 Endpoints News 网络研讨会
Feb 16, 2023 08:00 HKT
疫苗開發不斷變化的全球格局:Novotech 和 Endpoints News 網絡研討會
Feb 16, 2023 08:00 HKT
백신 개발 발전의 글로벌 환경: 노보텍 및 엔드포인트 뉴스 웨비나
Feb 16, 2023 08:00 HKT
<< Previous  Next >>
Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: